Positive prognostic impact of miR-210 in non-small cell lung cancer

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 272-278

  Eilertsen, Marte ^a   Andersen, Sigve ^a,b   Al Saad, Samer ^a,b   Richardsen, Elin ^a,b   Stenvold, Helge ^a,b   Hald, Sigurd M ^a   Al Shibli, Khalid ^a,c   Donnem, Tom ^a,b   Busund, Lill Tove ^a,b   Bremnes, Roy M ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

Biomarker; Cancer cells; MiR 210; NSCLC; Prognosis; Tumor stromal cells

Indexed keywords

LOCKED NUCLEIC ACID; MICRORNA 210;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STROMA CELL; TISSUE MICROARRAY; VERY ELDERLY;

BIOMARKER; CANCER CELLS; MIR-210; NSCLC; PROGNOSIS; TUMOR STROMAL CELLS;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; CARCINOMA, NON-SMALL-CELL LUNG; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; STROMAL CELLS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84892870976     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.005     Document Type: Article

References (44)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
4. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
5. Wightman B., Ha I., Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75:855-862.
6. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
7. Huang X., Le Q.T., Giaccia A.J. MiR-210-micromanager of the hypoxia pathway. Trends Mol Med 2010, 16:230-237.
8. Crosby M.E., Kulshreshtha R., Ivan M., Glazer P.M. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009, 69:1221-1229.
9. McCormick R.I., Blick C., Ragoussis J., Schoedel J., Mole D.R., Young A.C., et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer 2013, 108:1133-1142.
10. Andersen S., Donnem T., Al-Saad S., Al-Shibli K., Stenvold H., Busund L.T., et al. Correlation and coexpression of HIFs and NOTCH markers in NSCLC. Anticancer Res 2011, 31:1603-1606.
11. Andersen S., Donnem T., Stenvold H., Al-Saad S., Al-Shibli K., Busund L.T., et al. Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS ONE 2011, 6:e23847.
12. Andersen S., Eilertsen M., Donnem T., Al-Shibli K., Al-Saad S., Busund L.T., et al. Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer 2011, 72:294-302.
13. Eilertsen M., Pettersen I., Andersen S., Martinez I., Donnem T., Busund L.T., et al. In NSCLC, VEGF-A response to hypoxia may differ between squamous cell and adenocarcinoma histology. Anticancer Res 2012, 32:4729-4736.
14. Donnem T., Fenton C.G., Lonvik K., Berg T., Eklo K., Andersen S., et al. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS ONE 2012, 7:e29671.
15. Rami-Porta R., Chansky K., Goldstraw P. Updated lung cancer staging system. Future Oncol 2009, 5:1545-1553.
16. Donnem T., Al-Saad S., Al-Shibli K., Delghandi M.P., Persson M., Nilsen M.N., et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007, 13:6649-6657.
17. Kallioniemi O.P., Wagner U., Kononen J., Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001, 10:657-662.
18. Raponi M., Dossey L., Jatkoe T., Wu X., Chen G., Fan H., et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009, 69:5776-5783.
19. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
20. Cho W.C., Chow A.S., Au J.S. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer 2009, 45:2197-2206.
21. Xing L., Todd N.W., Yu L., Fang H., Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 2010, 23:1157-1164.
22. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070.
23. Porkka K.P., Pfeiffer M.J., Waltering K.K., Vessella R.L., Tammela T.L., Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007, 67:6130-6135.
24. Nishida N., Nagahara M., Sato T., Mimori K., Sudo T., Tanaka F., et al. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin Cancer Res 2012, 18:3054-3070.
25. Greither T., Wurl P., Grochola L., Bond G., Bache M., Kappler M., et al. Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer 2012, 130:1230-1235.
26. Camps C., Buffa F.M., Colella S., Moore J., Sotiriou C., Sheldon H., et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008, 14:1340-1348.
27. Gee H.E., Camps C., Buffa F.M., Patiar S., Winter S.C., Betts G., et al. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 2010, 116:2148-2158.
28. Foekens J.A., Sieuwerts A.M., Smid M., Look M.P., de Weerd V., Boersma A.W., et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 2008, 105:13021-13026.
29. Giannakakis A., Sandaltzopoulos R., Greshock J., Liang S., Huang J., Hasegawa K., et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2008, 7:255-264.
30. Tsuchiya S., Fujiwara T., Sato F., Shimada Y., Tanaka E., Sakai Y., et al. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem 2011, 286:420-428.
31. Huang X., Ding L., Bennewith K.L., Tong R.T., Welford S.M., Ang K.K., et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009, 35:856-867.
32. Wang H., Bian S., Yang C.S. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis 2011, 32:1881-1889.
33. Yoshioka Y., Kosaka N., Ochiya T., Kato T. Micromanaging iron homeostasis: hypoxia-inducible micro-RNA-210 suppresses iron homeostasis-related proteins. J Biol Chem 2012, 287:34110-34119.
34. Torti S.V., Torti F.M. Ironing out cancer. Cancer Res 2011, 71:1511-1514.
35. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401.
36. Faraonio R., Salerno P., Passaro F., Sedia C., Iaccio A., Bellelli R., et al. A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. Cell Death Differ 2012, 19:713-721.
37. Donnem T., Al-Saad S., Al-Shibli K., Andersen S., Busund L.T., Bremnes R.M. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 2008, 3:963-970.
38. Kim J.H., Park S.G., Song S.Y., Kim J.K., Sung J.H. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Cell Death Dis 2013, 4:e588.
39. Kaluz S., Kaluzova M., Liao S.Y., Lerman M., Stanbridge E.J. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show?. Biochim Biophys Acta 2009, 1795:162-172.
40. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-10518.
41. Roa W.H., Kim J.O., Razzak R., Du H., Guo L., Singh R., et al. Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. Clin Invest Med 2012, 35:E271.
42. Zhao A., Li G., Peoc'h M., Genin C., Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 2013, 94:115-120.
43. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-675.
44. Iorio M.V., Croce C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012, 4:143-159.